Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
Petros Grivas, Elizabeth R. Plimack, Arjun Vasant Balar, et al.
European Urology Oncology (2020) Vol. 3, Iss. 3, pp. 351-359
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Christopher Hoimes, Thomas W. Flaig, Matthew I. Milowsky, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 1, pp. 22-31
Open Access | Times Cited: 183
Case report: A rare case of delayed drug-induced hyponatremia in recurrent upper tract urothelial carcinoma following GC and Tislelizumab treatment
Zhijie Wang, Yan Nie, Shi-Bing Liang, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access | Times Cited: 1
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
Dharmesh Gopalakrishnan, Vadim S. Koshkin, Moshe Chaim Ornstein, et al.
Therapeutics and Clinical Risk Management (2018) Vol. Volume 14, pp. 1019-1040
Open Access | Times Cited: 61
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice
Petros Grivas, Neeraj Agarwal, Sumanta K. Pal, et al.
Cancer Treatment Reviews (2021) Vol. 97, pp. 102187-102187
Open Access | Times Cited: 47
Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
Giandomenico Roviello, Martina Catalano, Raffaella Santi, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4411-4411
Open Access | Times Cited: 47
Nanomedicine for Combination Urologic Cancer Immunotherapy
Yun Tian, Zhenzhu Liu, Jianbo Wang, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 546-546
Open Access | Times Cited: 13
Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis
Weiming Liang, Zhijin Wang, Zhilong Huang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
Shilpa Gupta, Miguel Á. Climent Durán, S.S. Sridhar, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104506-104506
Closed Access
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors
Gregory R. Pond, Archana M. Agarwal, Moshe Chaim Ornstein, et al.
Clinical Genitourinary Cancer (2021) Vol. 19, Iss. 5, pp. 425-433
Closed Access | Times Cited: 30
The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma
Jingwen Zhang, Meng Yang, Dongqun Wei, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma
Brigida Anna Maiorano, Giovanni Schinzari, Carmine Carbone, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
From Interferon to Checkpoint Inhibition Therapy—A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette–Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC)
Susanne Deininger, Péter Törzsök, Michael Mitterberger, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 694-694
Open Access | Times Cited: 14
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
Roberto Iacovelli, Chiara Ciccarese, Matteo Brunelli, et al.
Annals of Oncology (2022) Vol. 33, Iss. 11, pp. 1179-1185
Open Access | Times Cited: 14
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis
Daniel Vilarim Araújo, J. Connor Wells, Aaron R. Hansen, et al.
Journal of Geriatric Oncology (2021) Vol. 12, Iss. 5, pp. 820-826
Closed Access | Times Cited: 18
Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
Giandomenico Roviello, Martina Catalano, Raffaella Santi, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 13
Effect of Clinical Complete Remission Following Neoadjuvant Pembrolizumab or Chemotherapy in Bladder-Preservation Strategy in Patients with Muscle-Invasive Bladder Cancer Declining Definitive Local Therapy
Pei‐Hung Chang, Hung-Yi Chen, Yueh-Shih Chang, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 894-894
Open Access | Times Cited: 2
Current therapeutic options for glioblastoma and future perspectives
Elisa Aquilanti, Patrick Y. Wen
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 14, pp. 1629-1640
Closed Access | Times Cited: 9
Contemporary Systemic Therapies in Urothelial Carcinoma
JJ H. Zhang, Savannah L. Starr, Karim Chamie
Urology (2023) Vol. 174, pp. 150-158
Closed Access | Times Cited: 5
An iodine‑labelled Antibody–drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma
Yanan Ren, Teli Liu, Siming Li, et al.
International Journal of Pharmaceutics (2023) Vol. 651, pp. 123756-123756
Closed Access | Times Cited: 5
Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study
Elodie Dang, Alexandre Vallée, Coralie Lepage-Seydoux, et al.
Current Oncology (2022) Vol. 29, Iss. 2, pp. 945-955
Open Access | Times Cited: 8
Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction
Vaia Florou, Sonam Puri, Ignacio Garrido‐Laguna, et al.
Annals of Translational Medicine (2021) Vol. 9, Iss. 12, pp. 1035-1035
Open Access | Times Cited: 11
Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras
Ali Raza Khaki, Shasank Chennupati, Catherine R. Fedorenko, et al.
JCO Oncology Practice (2021) Vol. 17, Iss. 11, pp. e1728-e1737
Open Access | Times Cited: 9
Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy—A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin
Susanne Deininger, Péter Törzsök, David Oswald, et al.
Cancers (2021) Vol. 13, Iss. 13, pp. 3206-3206
Open Access | Times Cited: 9
Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?
Brian M. Russell, Leora Boussi, Joaquim Bellmunt
Drugs & Aging (2022) Vol. 39, Iss. 4, pp. 271-284
Open Access | Times Cited: 6
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
Trang T. Vu, Kyeongmin Kim, Millennium Manna, et al.
Pharmacological Research (2023) Vol. 199, pp. 107048-107048
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top